Bictegravir/Emtricitabine/Tenofovir Alafenamide

Each film-coated tablet contains 50 mg of Bictegravir (equivalent to 52.5 mg of Bictegravir sodium), 200 mg of Emtricitabine, and 25 mg of Tenofovir alafenamide (equivalent to 28 mg of tenofovir alafenamide fumarate).

INDICATIONS:

LuciBet is a three-drug combination of bictegravir (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14

Who have no antiretroviral treatment history or

• To replace the current antiretroviral regimen in those who are virologically suppressed (HIV1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir.

DOSAGE AND USE:

• Recommended dosage in adults and pediatric patients weighing at least 25 kg, or virologically-suppressed adults with estimated creatinine clearance below 15 mL/min receiving chronic hemodialysis: One tablet once daily with or without food.

• Recommended dosage in pregnant individuals who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known substitutions associated with resistance to the individual components of LuciBet: One tablet once daily with or without food.

If you miss a dose of LuciBet take your next dose as soon as you remember.

Do not take 2 doses at the same time to make up for your missed dose.

STORAGE:

In a dry place and store at 20°C to 25°C.

WARNINGS:

Keep medicine out of reach of Children.